Table 2.
Selected demographic and clinical characteristics according to progression-free survival and overall survival among ovarian cancer patients
| Variables | PFS | OS | ||
|---|---|---|---|---|
| No./Events | HR (95%CI)† | No./Events | HR (95%CI)† | |
| Age at diagnosis | ||||
| ≤ 50 | 257/101 | 1.00 (Ref) | 257/85 | 1.00 (Ref) |
| > 50 | 370/159 | 1.11 (0.86-1.44) | 370/147 | 1.26 (0.95-1.65) |
| Comorbidity | ||||
| No | 328/119 | 1.00 (Ref) | 328/102 | 1.00 (Ref) |
| Yes | 299/141 | 1.36 (1.06-1.75) | 299/130 | 1.50 (1.15-1.95) |
| Performance status | ||||
| 0-1 | 161/63 | 1.00 (Ref) | 161/52 | 1.00 (Ref) |
| 2 | 317/116 | 0.98 (0.71-1.35) | 317/103 | 1.11 (0.78-1.57) |
| ≥3 | 149/81 | 1.38 (0.96-1.98) | 149/77 | 1.42 (0.97-2.08) |
| Histological type (%) | ||||
| Serous | 449/212 | 1.00 (Ref) | 449/187 | 1.00 (Ref) |
| Non-serous | 178/48 | 0.79 (0.57-1.11) | 178/45 | 0.93 (0.66-1.32) |
| FIGO stage (%) | ||||
| I-II | 265/52 | 1.00 (Ref) | 265/39 | 1.00 (Ref) |
| III-IV | 362/208 | 2.68 (1.88-3.80) | 362/193 | 3.27 (2.22-4.82) |
| Residual disease | ||||
| None detectable | 395/114 | 1.00 (Ref) | 395/92 | 1.00 (Ref) |
| ≤ 1 cm | 114/68 | 1.97 (1.43-2.72) | 114/64 | 2.05 (1.46-2.88) |
| > 1 cm | 118/78 | 2.01 (1.46-2.76) | 118/76 | 2.37 (1.71-3.30) |
| Ascites | ||||
| No | 367/129 | 1.00 (Ref) | 367/110 | 1.00 (Ref) |
| Yes | 260/131 | 1.09 (0.83-1.43) | 260/122 | 1.31 (1.00-1.74) |
| Grading | ||||
| Grade 1 | 36/12 | 1.00 (Ref) | 36/9 | 1.00 (Ref) |
| Grade 2 | 169/64 | 1.40 (0.77-2.55) | 169/55 | 1.70 (0.85-3.40) |
| Grade 3 | 422/184 | 1.58 (0.83-3.00) | 422/168 | 1.79 (0.73-4.36) |
CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio; OS, overall survival; PFS, progression-free survival.
† HRs (95% CIs) for progression-free survival and overall survival were estimated by using multivariable proportional hazard models, mutually adjusted for all other variables listed in the table.